Atlas Trials

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

Clinical trial NCT07624838 · RECRUITING

Trial details

NCT number
NCT07624838
Sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Status
RECRUITING
Study type
OBSERVATIONAL
CD30-Positive Peripheral T-Cell Lymphoma
Start date
2026-02-15
Primary completion
2026-11-01
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.